Adverse Outcome Pathway on histone deacetylase inhibition leading to testicular atrophy:
The present AOP describes inhibition of histone deacetylase resulting in testicular atrophy. Histone deacetylase inhibitors (HDIs) are approved as anti-cancer drugs since HDIs have apoptotic effects in cancer cells. The intracellular mechanisms of induction of the spermatocyte apoptosis by HDIs are...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , |
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Paris
OECD Publishing
2021
|
| Series: | OECD Series on Adverse Outcome Pathways
|
| Subjects: | |
| Online Access: | Volltext |
| Summary: | The present AOP describes inhibition of histone deacetylase resulting in testicular atrophy. Histone deacetylase inhibitors (HDIs) are approved as anti-cancer drugs since HDIs have apoptotic effects in cancer cells. The intracellular mechanisms of induction of the spermatocyte apoptosis by HDIs are suggested as histone deacetylase (HDAC) inhibition as MIE, histone acetylation increase, disrupted cell cycle, apoptosis, and spermatocyte depletion as KEs. The adverse outcome has been defined as testicular atrophy. The HDIs inhibit deacetylation of the histone, leading to an increase in histone acetylation. The apoptosis induced by disrupted cell cycle leads to spermatocyte depletion and testis atrophy. Testicular toxicity is of interest for human health risk assessment especially in terms of reproductive and developmental toxicity, however, the testicular toxicity has not been fully elucidated. This AOP may be one of the pathways induced by HDIs, which suggests the pathway networks of protein hyperacetylations |
| Physical Description: | 1 Online-Ressource (64 Seiten) |
| DOI: | 10.1787/b9c4bdb2-en |
Staff View
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV047928164 | ||
| 003 | DE-604 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 220413s2021 xx o|||| 00||| eng d | ||
| 024 | 7 | |a 10.1787/b9c4bdb2-en |2 doi | |
| 035 | |a (ZDB-13-SOC)069856311 | ||
| 035 | |a (OCoLC)1312703534 | ||
| 035 | |a (DE-599)BVBBV047928164 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-384 |a DE-91 |a DE-473 |a DE-824 |a DE-29 |a DE-739 |a DE-355 |a DE-20 |a DE-1028 |a DE-1049 |a DE-188 |a DE-521 |a DE-861 |a DE-898 |a DE-92 |a DE-573 |a DE-19 | ||
| 100 | 1 | |a Tanabe, Shihori |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Adverse Outcome Pathway on histone deacetylase inhibition leading to testicular atrophy |c Shihori Tanabe, Akihiko Hirose and Takashi Yamada |
| 264 | 1 | |a Paris |b OECD Publishing |c 2021 | |
| 300 | |a 1 Online-Ressource (64 Seiten) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a OECD Series on Adverse Outcome Pathways | |
| 520 | |a The present AOP describes inhibition of histone deacetylase resulting in testicular atrophy. Histone deacetylase inhibitors (HDIs) are approved as anti-cancer drugs since HDIs have apoptotic effects in cancer cells. The intracellular mechanisms of induction of the spermatocyte apoptosis by HDIs are suggested as histone deacetylase (HDAC) inhibition as MIE, histone acetylation increase, disrupted cell cycle, apoptosis, and spermatocyte depletion as KEs. The adverse outcome has been defined as testicular atrophy. The HDIs inhibit deacetylation of the histone, leading to an increase in histone acetylation. The apoptosis induced by disrupted cell cycle leads to spermatocyte depletion and testis atrophy. Testicular toxicity is of interest for human health risk assessment especially in terms of reproductive and developmental toxicity, however, the testicular toxicity has not been fully elucidated. This AOP may be one of the pathways induced by HDIs, which suggests the pathway networks of protein hyperacetylations | ||
| 650 | 4 | |a Social Issues/Migration/Health | |
| 650 | 4 | |a Environment | |
| 700 | 1 | |a Hirose, Akihiko |4 ctb | |
| 700 | 1 | |a Yamada, Takashi |4 ctb | |
| 856 | 4 | 0 | |u https://doi.org/10.1787/b9c4bdb2-en |x Verlag |z kostenfrei |3 Volltext |
| 912 | |a ZDB-13-SOC | ||
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-033309657 | |
Record in the Search Index
| _version_ | 1818805950527569920 |
|---|---|
| adam_text | |
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author | Tanabe, Shihori |
| author2 | Hirose, Akihiko Yamada, Takashi |
| author2_role | ctb ctb |
| author2_variant | a h ah t y ty |
| author_facet | Tanabe, Shihori Hirose, Akihiko Yamada, Takashi |
| author_role | aut |
| author_sort | Tanabe, Shihori |
| author_variant | s t st |
| building | Verbundindex |
| bvnumber | BV047928164 |
| collection | ZDB-13-SOC |
| ctrlnum | (ZDB-13-SOC)069856311 (OCoLC)1312703534 (DE-599)BVBBV047928164 |
| discipline | Wirtschaftswissenschaften |
| discipline_str_mv | Wirtschaftswissenschaften |
| doi_str_mv | 10.1787/b9c4bdb2-en |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000zc 4500</leader><controlfield tag="001">BV047928164</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">220413s2021 xx o|||| 00||| eng d</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1787/b9c4bdb2-en</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-13-SOC)069856311</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1312703534</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV047928164</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-384</subfield><subfield code="a">DE-91</subfield><subfield code="a">DE-473</subfield><subfield code="a">DE-824</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-739</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-1028</subfield><subfield code="a">DE-1049</subfield><subfield code="a">DE-188</subfield><subfield code="a">DE-521</subfield><subfield code="a">DE-861</subfield><subfield code="a">DE-898</subfield><subfield code="a">DE-92</subfield><subfield code="a">DE-573</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tanabe, Shihori</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Adverse Outcome Pathway on histone deacetylase inhibition leading to testicular atrophy</subfield><subfield code="c">Shihori Tanabe, Akihiko Hirose and Takashi Yamada</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Paris</subfield><subfield code="b">OECD Publishing</subfield><subfield code="c">2021</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (64 Seiten)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">OECD Series on Adverse Outcome Pathways</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The present AOP describes inhibition of histone deacetylase resulting in testicular atrophy. Histone deacetylase inhibitors (HDIs) are approved as anti-cancer drugs since HDIs have apoptotic effects in cancer cells. The intracellular mechanisms of induction of the spermatocyte apoptosis by HDIs are suggested as histone deacetylase (HDAC) inhibition as MIE, histone acetylation increase, disrupted cell cycle, apoptosis, and spermatocyte depletion as KEs. The adverse outcome has been defined as testicular atrophy. The HDIs inhibit deacetylation of the histone, leading to an increase in histone acetylation. The apoptosis induced by disrupted cell cycle leads to spermatocyte depletion and testis atrophy. Testicular toxicity is of interest for human health risk assessment especially in terms of reproductive and developmental toxicity, however, the testicular toxicity has not been fully elucidated. This AOP may be one of the pathways induced by HDIs, which suggests the pathway networks of protein hyperacetylations</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Social Issues/Migration/Health</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Environment</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hirose, Akihiko</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamada, Takashi</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1787/b9c4bdb2-en</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033309657</subfield></datafield></record></collection> |
| id | DE-604.BV047928164 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T19:34:54Z |
| indexdate | 2024-12-18T19:02:01Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033309657 |
| oclc_num | 1312703534 |
| open_access_boolean | 1 |
| owner | DE-384 DE-91 DE-BY-TUM DE-473 DE-BY-UBG DE-824 DE-29 DE-739 DE-355 DE-BY-UBR DE-20 DE-1028 DE-1049 DE-188 DE-521 DE-861 DE-898 DE-BY-UBR DE-92 DE-573 DE-19 DE-BY-UBM |
| owner_facet | DE-384 DE-91 DE-BY-TUM DE-473 DE-BY-UBG DE-824 DE-29 DE-739 DE-355 DE-BY-UBR DE-20 DE-1028 DE-1049 DE-188 DE-521 DE-861 DE-898 DE-BY-UBR DE-92 DE-573 DE-19 DE-BY-UBM |
| physical | 1 Online-Ressource (64 Seiten) |
| psigel | ZDB-13-SOC |
| publishDate | 2021 |
| publishDateSearch | 2021 |
| publishDateSort | 2021 |
| publisher | OECD Publishing |
| record_format | marc |
| series2 | OECD Series on Adverse Outcome Pathways |
| spelling | Tanabe, Shihori Verfasser aut Adverse Outcome Pathway on histone deacetylase inhibition leading to testicular atrophy Shihori Tanabe, Akihiko Hirose and Takashi Yamada Paris OECD Publishing 2021 1 Online-Ressource (64 Seiten) txt rdacontent c rdamedia cr rdacarrier OECD Series on Adverse Outcome Pathways The present AOP describes inhibition of histone deacetylase resulting in testicular atrophy. Histone deacetylase inhibitors (HDIs) are approved as anti-cancer drugs since HDIs have apoptotic effects in cancer cells. The intracellular mechanisms of induction of the spermatocyte apoptosis by HDIs are suggested as histone deacetylase (HDAC) inhibition as MIE, histone acetylation increase, disrupted cell cycle, apoptosis, and spermatocyte depletion as KEs. The adverse outcome has been defined as testicular atrophy. The HDIs inhibit deacetylation of the histone, leading to an increase in histone acetylation. The apoptosis induced by disrupted cell cycle leads to spermatocyte depletion and testis atrophy. Testicular toxicity is of interest for human health risk assessment especially in terms of reproductive and developmental toxicity, however, the testicular toxicity has not been fully elucidated. This AOP may be one of the pathways induced by HDIs, which suggests the pathway networks of protein hyperacetylations Social Issues/Migration/Health Environment Hirose, Akihiko ctb Yamada, Takashi ctb https://doi.org/10.1787/b9c4bdb2-en Verlag kostenfrei Volltext |
| spellingShingle | Tanabe, Shihori Adverse Outcome Pathway on histone deacetylase inhibition leading to testicular atrophy Social Issues/Migration/Health Environment |
| title | Adverse Outcome Pathway on histone deacetylase inhibition leading to testicular atrophy |
| title_auth | Adverse Outcome Pathway on histone deacetylase inhibition leading to testicular atrophy |
| title_exact_search | Adverse Outcome Pathway on histone deacetylase inhibition leading to testicular atrophy |
| title_exact_search_txtP | Adverse Outcome Pathway on histone deacetylase inhibition leading to testicular atrophy |
| title_full | Adverse Outcome Pathway on histone deacetylase inhibition leading to testicular atrophy Shihori Tanabe, Akihiko Hirose and Takashi Yamada |
| title_fullStr | Adverse Outcome Pathway on histone deacetylase inhibition leading to testicular atrophy Shihori Tanabe, Akihiko Hirose and Takashi Yamada |
| title_full_unstemmed | Adverse Outcome Pathway on histone deacetylase inhibition leading to testicular atrophy Shihori Tanabe, Akihiko Hirose and Takashi Yamada |
| title_short | Adverse Outcome Pathway on histone deacetylase inhibition leading to testicular atrophy |
| title_sort | adverse outcome pathway on histone deacetylase inhibition leading to testicular atrophy |
| topic | Social Issues/Migration/Health Environment |
| topic_facet | Social Issues/Migration/Health Environment |
| url | https://doi.org/10.1787/b9c4bdb2-en |
| work_keys_str_mv | AT tanabeshihori adverseoutcomepathwayonhistonedeacetylaseinhibitionleadingtotesticularatrophy AT hiroseakihiko adverseoutcomepathwayonhistonedeacetylaseinhibitionleadingtotesticularatrophy AT yamadatakashi adverseoutcomepathwayonhistonedeacetylaseinhibitionleadingtotesticularatrophy |